Equities Analysts Offer Predictions for CRSP FY2026 Earnings

Key Points

• Brookline Capital cut its FY2026 EPS estimate for CRISPR Therapeutics to $2.63 from $2.75 and projects FY2027 EPS of $4.81, while the current consensus full-year EPS is a loss of ($5.16) per share.
• Analyst sentiment is mixed—11 Buys, 8 Holds and 2 Sells—yielding a consensus rating of Hold and an average price target of $68.11, with individual targets ranging roughly $44–$82.
• Insiders have been net sellers, including CEO Samarth Kulkarni (50,895 shares) and the general counsel (1,076 shares); insiders sold 56,213 shares (~$3.81M) over the past three months and now own 4.10% of the stock.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Brookline Capital Management lowered their FY2026 earnings estimates for CRISPR Therapeutics in a research note issued on Monday, November 10th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of $2.63 for the year, down from their prior forecast of $2.75. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics' FY2027 earnings at $4.81 EPS.

Several other research analysts have also recently issued reports on the company. JPMorgan Chase & Co. started coverage on CRISPR Therapeutics in a research report on Thursday, September 18th. They issued an "overweight" rating and a $70.00 price objective for the company. Barclays increased their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Chardan Capital reissued a "buy" rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Robert W. Baird dropped their target price on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a "neutral" rating for the company in a report on Tuesday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of CRISPR Therapeutics in a research report on Wednesday, October 8th. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and an average price target of $68.11.

CRISPR Therapeutics Trading Down 1.0%

Shares of CRSP stock opened at $54.58 on Tuesday. The stock has a 50 day simple moving average of $62.98 and a 200-day simple moving average of $53.33. The company has a market cap of $4.96 billion, a price-to-earnings ratio of -10.05 and a beta of 1.89. CRISPR Therapeutics has a 12-month low of $30.04 and a 12-month high of $78.48.

Institutional Trading of CRISPR Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SVB Wealth LLC acquired a new stake in shares of CRISPR Therapeutics during the 1st quarter worth about $25,000. Costello Asset Management INC purchased a new position in shares of CRISPR Therapeutics during the first quarter valued at approximately $27,000. Atlantic Union Bankshares Corp acquired a new stake in CRISPR Therapeutics during the second quarter worth approximately $33,000. Thompson Investment Management Inc. acquired a new stake in CRISPR Therapeutics during the third quarter worth approximately $33,000. Finally, Optiver Holding B.V. grew its stake in CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company's stock worth $33,000 after acquiring an additional 210 shares during the period. Hedge funds and other institutional investors own 69.20% of the company's stock.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 1,076 shares of the firm's stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares of the company's stock, valued at $5,554,573.20. This trade represents a 1.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 50,895 shares of the company's stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 56,213 shares of company stock valued at $3,810,458. Corporate insiders own 4.10% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.